Sanofi Consumer Healthcare India Ltd vs Venmax Drugs Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Sanofi Consumer Healthcare India Ltd is ₹ 4802 as of 18 May 15:30 . The P/E Ratio of Sanofi Consumer Healthcare India Ltd changed from 62.6 on December 2024 to 62.6 on December 2024 . This represents a CAGR of 0.00% over 1 yearsThe P/E Ratio of Venmax Drugs & Pharmaceuticals Ltd changed from 0 on March 2021 to 0 on December 2024 . This represents a CAGR of 0.0% over 7 years The Market Cap of Sanofi Consumer Healthcare India Ltd changed from ₹ 11347 crore on December 2024 to ₹ 11347 crore on December 2024 . This represents a CAGR of 0.00% over 1 yearsThe Market Cap of Venmax Drugs & Pharmaceuticals Ltd changed from ₹ 14.94 crore on March 2025 to ₹ 0 crore on December 2024 . This represents a CAGR of -100.00% over 3 years The revenue of Sanofi Consumer Healthcare India Ltd for the Mar '26 is ₹ 0 crore as compare to the Jun '26 revenue of ₹ 234.8 crore. This represent the decline of -100% The revenue of Venmax Drugs & Pharmaceuticals Ltd for the Mar '26 is ₹ 4.04 crore as compare to the Jun '26 revenue of ₹ 0 crore. This represent the growth of 9.2233718E16% The ebitda of Sanofi Consumer Healthcare India Ltd for the Mar '26 is ₹ 0 crore as compare to the Jun '26 ebitda of ₹ 94.4 crore. This represent the decline of -100% The ebitda of Venmax Drugs & Pharmaceuticals Ltd for the Mar '26 is ₹ 0.11 crore as compare to the Jun '26 ebitda of ₹ 0 crore. This represent the growth of 9.2233718E16% The net profit of Sanofi Consumer Healthcare India Ltd changed from ₹ 62.7 crore to ₹ 0 crore over 9 quarters. This represents a CAGR of -100.00% The net profit of Venmax Drugs & Pharmaceuticals Ltd changed from ₹ 0.01 crore to ₹ 0.11 crore over 9 quarters. This represents a CAGR of 190.30% The Dividend Payout of Sanofi Consumer Healthcare India Ltd changed from 6.06 % on December 2023 to 69.89 % on December 2024 . This represents a CAGR of 239.60% over 2 yearsThe Dividend Payout of Venmax Drugs & Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on December 2024 . This represents a CAGR of 0.0% over 7 years .

About Sanofi Consumer Healthcare India Ltd

Sanofi Consumer Healthcare India Limited was incorporated on May 10, 2023, as part of Sanofi's global strategy to establish a standalone Consumer Healthcare business.
This strategic move resulted in the demerger of the Consumer Healthcare business from Sanofi India Limited (SIL) into the Company through a Scheme of Arrangement, thereby creating a distinct legal entity.
The Scheme of Arrangement, which was sanctioned by the National Company Law Tribunal, Mumbai (NCLT) enabled the seamless transfer and vesting of all assets, liabilities, and operations of SIL to the Company. Pursuant to the Scheme becoming effective, the Consumer Healthcare Division (CHC) business of Sanofi India Limited (SIL) got demerged into the Company as a going concern through the Scheme of Arrangement and became effective from June 1, 2024.

About Venmax Drugs & Pharmaceuticals Ltd

Venmax Drugs & Pharmaceuticals Limited, (VDPL) was initially incorporated as Private Company as 'Yenkay Medico Private Limited', on 28 September, 1998.
The Company thereafter changed its name to 'Yenkey Drugs & Pharmaceuticals Private Limited' on 18 January, 1995.
It became a Public Limited Company on February 3, 1995 as 'Yenkey Drugs & Pharmaceuticals Limited'.
Finally, the Company changed its name to 'Venmax Drugs & Pharmaceuticals Limited' on April 13, 2009. For the past six months, Company focused on establishing chain of Medical Stores with a brand name as 'Ananya Pharma' under the Venmax Drugs & Pharma Limited, with the backing support of Formulations plant (Suzichem Labs).
At present, Company is engaged in the business of pharmaceutical products, drug intermediaries & API's etc. The Company is developing the oncology products in R&D.

FAQs for the comparison of Sanofi Consumer Healthcare India Ltd and Venmax Drugs & Pharmaceuticals Ltd

Which company has a larger market capitalization, Sanofi Consumer Healthcare India Ltd or Venmax Drugs & Pharmaceuticals Ltd?

Market cap of Sanofi Consumer Healthcare India Ltd is 11,059 Cr while Market cap of Venmax Drugs & Pharmaceuticals Ltd is 26 Cr

What are the key factors driving the stock performance of Sanofi Consumer Healthcare India Ltd and Venmax Drugs & Pharmaceuticals Ltd?

The stock performance of Sanofi Consumer Healthcare India Ltd and Venmax Drugs & Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Sanofi Consumer Healthcare India Ltd and Venmax Drugs & Pharmaceuticals Ltd?

As of May 18, 2026, the Sanofi Consumer Healthcare India Ltd stock price is INR ₹4802.25. On the other hand, Venmax Drugs & Pharmaceuticals Ltd stock price is INR ₹23.07.

How do dividend payouts of Sanofi Consumer Healthcare India Ltd and Venmax Drugs & Pharmaceuticals Ltd compare?

To compare the dividend payouts of Sanofi Consumer Healthcare India Ltd and Venmax Drugs & Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.